Shares of Arcadia Biosciences Inc (NASDAQ:RKDA) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokers have set a 12-month consensus target price of $20.00 for the company and are expecting that the company will post ($0.61) earnings per share for the current quarter, according to Zacks. Zacks has also given Arcadia Biosciences an industry rank of 245 out of 255 based on the ratings given to related companies.
A number of research analysts have recently commented on the company. National Securities assumed coverage on Arcadia Biosciences in a research report on Wednesday. They set a “buy” rating and a $15.00 price target on the stock. Zacks Investment Research raised Arcadia Biosciences from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research report on Thursday, February 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Arcadia Biosciences in a research report on Thursday, February 28th.
Hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in shares of Arcadia Biosciences during the 3rd quarter valued at $121,000. Dimensional Fund Advisors LP bought a new stake in shares of Arcadia Biosciences during the 3rd quarter valued at $112,000. Finally, Vanguard Group Inc bought a new stake in shares of Arcadia Biosciences during the 3rd quarter valued at $91,000. 5.91% of the stock is currently owned by hedge funds and other institutional investors.
RKDA stock traded down $0.08 during midday trading on Friday, hitting $5.93. The company’s stock had a trading volume of 79,689 shares, compared to its average volume of 771,236. Arcadia Biosciences has a 1 year low of $2.64 and a 1 year high of $25.88. The stock has a market cap of $28.33 million, a P/E ratio of -1.11 and a beta of -2.00.
Arcadia Biosciences (NASDAQ:RKDA) last posted its quarterly earnings data on Wednesday, March 27th. The basic materials company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.76) by $0.62. Arcadia Biosciences had a negative return on equity of 233.26% and a negative net margin of 920.77%. The business had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $0.30 million. As a group, equities research analysts forecast that Arcadia Biosciences will post -2.4 earnings per share for the current year.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.
Further Reading: Stock Symbols Definition, Examples, Lookup
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.